Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Non-interventional, Registry Study of Patients Initiating Pharmacologic Therapy for Overactive Bladder in Taiwan, Korea and China

Trial Profile

A Prospective, Non-interventional, Registry Study of Patients Initiating Pharmacologic Therapy for Overactive Bladder in Taiwan, Korea and China

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Darifenacin (Primary) ; Fesoterodine (Primary) ; Imidafenacin (Primary) ; Mirabegron (Primary) ; Oxybutynin (Primary) ; Propiverine (Primary) ; Solifenacin (Primary) ; Tolterodine (Primary) ; Trospium chloride (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 08 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 04 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top